Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017–2019

Abstract

Ceftaroline is an important therapeutic option for community-acquired pneumonia (CAP). Antimicrobial susceptibility to ceftaroline and other antimicrobial agents against Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilusinfluenzae isolates collected worldwide from identified respiratory tract sources is reported by age groups (0-18, 19-65, and >65years). Antimicrobial susceptibility of isolates, collected as part of the ATLAS program (2017-2019), was performed per EUCAST/CLSI guidelines. S. aureus (N=7103; methicillin-susceptible S. aureus [MSSA]=4203; methicillin-resistant S. aureus [MRSA]=2791), S. pneumoniae (N=4823; EUCAST/CLSI, penicillin-intermediate S. pneumoniae [PISP]=1408/870; penicillin-resistant S. pneumoniae [PRSP]=455/993), and H. influenzae (N=3850; β-lactamase [βL]-negative=3097; βL-positive=753) isolates were collected from respiratory tract specimens. Susceptibility to ceftaroline was 89.08%-97.83% for S. aureus, 99.95%-100% for MSSA, and 78.07%-92.74% for MRSA isolates across age groups; S. aureus as well as MRSA isolates derived from the 0-18 years age group demonstrated the highest susceptibility rates to ceftaroline. Susceptibility to ceftaroline was 98.25%-99.77% for S.pneumoniae, 99.74%-100% for PISP, and 86.23%-99.04% for PRSP isolates across age groups. Across all age groups, susceptibility to ceftaroline was 89.53%-99.70% for H.influenzae, 93.02%-100% for βL-negative, and 77.78%-98.35% for βL-positive isolates. Irrespective of age, susceptibility to ceftaroline was high among the majority of S. aureus, S. pneumoniae, and H. influenzae isolates collected in this study.